Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimer Disease: early-phase trial registry
155 of 312 indexed Alzheimer Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #25 of 28,707 conditions by registered trial count.
312 US clinical trials · 155 currently recruiting · #25 of 28,707 conditions by registered trial count
Alzheimer Disease: 312 US clinical trials tracked, 155 recruiting.
Alzheimer Disease is the subject of 312 registered US clinical trials on ClinicalTrials.gov, 155 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 104 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 13 of these trials.
Enrollment posture brief
Registry condition alzheimer-disease
OPEN 155 | RECR 50% | LATE 26 | EARLY 104 | RANK #25 | SPON 13
Volume-matched condition peers
Nearest open-share peer: PTSD (50% recruiting · 155 trials)
Alzheimer Disease lists 155 open slots (50% of 312 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Alzheimer Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimer Disease is recruiting above its size-band peers.
155 of 312 indexed trials (49.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimer Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 13 of 312 trials (4.2%). 178 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimer Disease enrolment sits around 100 participants.
Median target enrolment is 100 among the 307 trials that report a genuine target (sentinel values excluded). 151 of those (49.2%) plan for fewer than 100 participants.
-
Alzheimer Disease research is mostly interventional.
255 interventional and 57 observational studies make up this index (81.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
312 total, page 3 of 7
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease
Massachusetts General Hospital
NCT05904132
Promoting Independence With Compensatory Cognitive Rehabilitation
University of Delaware
NCT04820335
Comparing Structured Retrieval Practice and Reading-Based Education for Dementia Caregivers
Virginia Wesleyan University
NCT07413406
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl
Washington University School of Medicine
NCT06439992
Gamma-Music Based Intervention for Mild Alzheimer's Disease
Northeastern University
NCT05984524
I-CARE Rural Pilot: Intervention for Rural-Dwelling Dementia Caregivers
Richard Holden
NCT07054385
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
University of California, San Diego
NCT06548191
Music Therapy for Patients With Alzheimer's Disease
Johns Hopkins University
NCT05151562
Aβ Dynamics in LLMD
NYU Langone Health
NCT05004987
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
University of Texas at Austin
NCT05741853
Senicapoc in Alzheimer's Disease
University of California, Davis
NCT04804241
Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD)
University of California, Los Angeles
NCT06597942
Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease
Baylor College of Medicine
NCT04740580
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
Johns Hopkins University
NCT04601038
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Massachusetts Institute of Technology
NCT05655195
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
InSightec
NCT03671889
MR Evaluation of Cerebrospinal Fluid (CSF) Dynamics
Mayo Clinic
NCT04099823
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company
NCT06297590
Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
University of Colorado, Denver
NCT04902703
Systemic and Central Inflammation in AD
The Methodist Hospital Research Institute
NCT06384378
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
Herrick Medical
NCT05295615
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
Indiana University
NCT06403345
DECIDE: Dyads and Families
Emory University
NCT05139290
Phase II Clinical Trial of Interleukin-2 in AD
The Methodist Hospital Research Institute
NCT06096090
Rapamycin - Effects on Alzheimer's and Cognitive Health
The University of Texas Health Science Center at San Antonio
NCT04629495
Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease
Rhode Island Hospital
NCT05599425
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Mclean Hospital
NCT05245903
Bumetanide in Patients With Alzheimer's Disease
Stanford University
NCT06052163
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals
Indiana University
NCT06099197
R21 Roche: 3-Way Tau Tracers in AD
Washington University School of Medicine
NCT05464368
An Objective Assessment Tool for Evaluating Functioning in Older Adults
Stanford University
NCT06489847
Nicotinic Acid for the Treatment of Alzheimer's Disease
Indiana University
NCT06582706
Assess Fibrin in Brains With AD/ADRD
Massachusetts General Hospital
NCT05336695
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
Georgia State University
NCT05205980
Combating Alzheimer's Through Sleep and Exercise
University of Miami
NCT04855630
Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Covenant Health, US
NCT07222280
Improving Access to Care for Veterans With Memory Loss
VA Pittsburgh Healthcare System
NCT07117162
Open-Label Extension Protocol to SNK01-AD01 Study
NKGen Biotech
NCT07228078
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Massachusetts General Hospital
NCT06538311
Indian Transforming Alzheimer's Care Training (INTACT)
Washington State University
NCT06397339
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Amydis
NCT06514001
Advancing Alzheimer's Care: Home-based tDCS for Affective Symptoms
The University of Texas Health Science Center at San Antonio
NCT06801639
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Johns Hopkins University
NCT04123314
Neuroinflammation Imaging in AD
University of Pennsylvania
NCT04274998
Sensory-Evoked Cortical Gamma Oscillation
University of Tennessee Medical Center
NCT05206305
Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease
Baylor College of Medicine
NCT06835283
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
Michal Schnaider Beeri, Ph.D.
NCT07392723
OCT Angiography and NRAI in Dementia
Oregon Health and Science University
NCT03761381
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
Regeneration Biomedical
NCT05667649
Low-Intensity Focused Ultrasound (LIFU) Neuromodulation
Ali Rezai
NCT05997030
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 51 |
| Phase 3 | 18 |
| Phase 4 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Alzheimer Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Alzheimer Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Alzheimer Disease page
312 registered trials, 155 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 155 Alzheimer Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Alzheimer Disease trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alzheimer Disease condition card totals 312 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.